Save on Ojemda with Coupons, Discounts & Savings Programs

Ojemda is the brand name for tovorafenib and is available as an oral tablet and oral suspension.

Ojemda is available as a 100 mg oral tablet and a 25 mg/mL oral suspension.

Ojemda is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with certain types of brain tumors.

Ojemda is a targeted cancer therapy that works as a pan-RAF kinase inhibitor. It blocks specific proteins (kinases) involved in cell growth, which helps to slow or stop the growth of cancer cells in tumors with certain genetic mutations.

The recommended dose of Ojemda is based on body surface area and is taken by mouth once weekly, with or without food.

Ojemda is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Ojemda:

• Rash
• Hair color changes
• Fatigue
• Viral infection
• Vomiting
• Headache
• Fever
• Dry skin
• Constipation
• Nausea
• Acne
• Upper respiratory tract infection

Serious side effects are rare with Ojemda. Contact your healthcare provider immediately if you experience any of the following:

• Bleeding problems, such as nose bleeds or bleeding from the tumor
• Skin reactions, including sensitivity to sunlight (photosensitivity)
• Liver problems
• Slowing of growth (height) in children

The following medications may interact with Ojemda:

• Moderate and strong CYP2C8 inhibitors
• Moderate and strong CYP2C8 inducers
• Certain CYP3A substrates
• Hormonal contraceptives

Teva Pharmaceuticals

Based on findings from animal studies and its mechanism of action, Ojemda may harm your unborn baby. Females of reproductive potential should use effective non-hormonal contraception during treatment and for 28 days after the last dose, since Ojemda can make some hormonal contraceptives ineffective. Male patients with female partners of reproductive potential should use effective nonhormonal contraception during treatment and for 2 weeks after the last dose.

• Tovorafenib